Advisory Commission on Childhood Vaccines; Notice of Meeting, 6166 [E9-2462]

Download as PDF 6166 Federal Register / Vol. 74, No. 23 / Thursday, February 5, 2009 / Notices and the Agency for Toxic Substances and Disease Registry. Dated: January 30, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–2447 Filed 2–4–09; 8:45 am] statement, may announce it at the time of the comment period. These persons will be allocated time as it permits. For Further Information Contact: Anyone requiring information regarding the ACCV should contact Michelle Herzog, DVIC, HSB, HRSA, Room 11C–26, 5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443– 6593 or e-mail: mherzog@hrsa.gov. Dated: January 26, 2009. Alexandra Huttinger, Director, Division of Policy Review and Coordination. [FR Doc. E9–2462 Filed 2–4–09; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4165–15–P Advisory Commission on Childhood Vaccines; Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting: rwilkins on PROD1PC63 with NOTICES Health Resources and Services Administration National Institutes of Health Name: Advisory Commission on Childhood Vaccines (ACCV). Date and Time: March 5, 2009, 1 p.m. to 5:30 p.m. EST., March 6, 2009, 9 a.m. to 12:30 p.m. EST. Place: Parklawn Building (and via audio conference call), Conference Rooms G & H, 5600 Fishers Lane, Rockville, MD 20857. The ACCV will meet on Thursday, March 5 from 1 p.m. to 5:30 p.m. (EST) and Friday, March 6 from 9 a.m. to 12:30 p.m. (EST). The public can join the meeting via audio conference call by dialing 1–888–790–3149 on March 5 & 6 and providing the following information: Leader’s Name: Dr. Geoffrey Evans. Password: ACCV. Agenda: The agenda items for the March meeting will include, but are not limited to: Updates from the Division of Vaccine Injury Compensation (DVIC), Department of Justice, National Vaccine Program Office, Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health), and Center for Biologics, Evaluation and Research (Food and Drug Administration). Agenda items are subject to change as priorities dictate. Public Comments: Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to: Michelle Herzog, DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services Administration (HRSA), Room 11C–26, 5600 Fishers Lane, Rockville, Maryland 20857 or e-mail: mherzog@hrsa.gov. Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. DVIC will notify each presenter by mail or telephone of their assigned presentation time. Persons who do not file an advance request for a presentation, but desire to make an oral Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. VerDate Nov<24>2008 16:34 Feb 04, 2009 Jkt 217001 Center for Scientific Review; Notice of Closed Meetings Name of Committee: Center for Scientific Review Special Emphasis Panel, Gene Therapy and Inborn Errors. Date: February 11–13, 2009. Time: 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Richard Panniers, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2212, MSC 7890, Bethesda, MD 20892, (301) 435– 1741, pannierr@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel Vector. Date: February 13, 2009. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Catamaran Resort, 3999 Mission Boulevard, San Diego, CA 92109. PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 Contact Person: Alexander D. Politis, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3210, MSC 7808, Bethesda, MD 20892, (301) 435– 1150, politisa@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Oncology Signaling Member Conflict. Date: February 16, 2009. Time: 11 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Mary Bell, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6188, MSC 7804, Bethesda, MD 20892, 301–451–8754, bellmar@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Immunology: Member Conflicts and Special Grant Applications. Date: February 17–18, 2009. Time: 10 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Stephen M. Nigida, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4212, MSC 7812, Bethesda, MD 20892, 301–435– 1222, nigidas@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Small Business Biomedical Sensing, Measurement and Instrumentation. Date: February 18, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bahia Resort Hotel, 998 W. Mission Bay Drive, San Diego, CA 92109. Contact Person: Guo Feng Xu, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, 301–435– 1032, xuguofen@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Complement, Vaccines, and Host Defense. Date: February 18, 2009. Time: 1 p.m. to 4 p.m. E:\FR\FM\05FEN1.SGM 05FEN1

Agencies

[Federal Register Volume 74, Number 23 (Thursday, February 5, 2009)]
[Notices]
[Page 6166]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-2462]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Advisory Commission on Childhood Vaccines; Notice of Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), notice is hereby given of the following 
meeting:

    Name: Advisory Commission on Childhood Vaccines (ACCV).
    Date and Time: March 5, 2009, 1 p.m. to 5:30 p.m. EST., March 6, 
2009, 9 a.m. to 12:30 p.m. EST.
    Place: Parklawn Building (and via audio conference call), 
Conference Rooms G & H, 5600 Fishers Lane, Rockville, MD 20857.
    The ACCV will meet on Thursday, March 5 from 1 p.m. to 5:30 p.m. 
(EST) and Friday, March 6 from 9 a.m. to 12:30 p.m. (EST). The 
public can join the meeting via audio conference call by dialing 1-
888-790-3149 on March 5 & 6 and providing the following information:
    Leader's Name: Dr. Geoffrey Evans.
    Password: ACCV.
    Agenda: The agenda items for the March meeting will include, but 
are not limited to: Updates from the Division of Vaccine Injury 
Compensation (DVIC), Department of Justice, National Vaccine Program 
Office, Immunization Safety Office (Centers for Disease Control and 
Prevention), National Institute of Allergy and Infectious Diseases 
(National Institutes of Health), and Center for Biologics, 
Evaluation and Research (Food and Drug Administration). Agenda items 
are subject to change as priorities dictate.
    Public Comments: Persons interested in providing an oral 
presentation should submit a written request, along with a copy of 
their presentation to: Michelle Herzog, DVIC, Healthcare Systems 
Bureau (HSB), Health Resources and Services Administration (HRSA), 
Room 11C-26, 5600 Fishers Lane, Rockville, Maryland 20857 or e-mail: 
mherzog@hrsa.gov. Requests should contain the name, address, 
telephone number, and any business or professional affiliation of 
the person desiring to make an oral presentation. Groups having 
similar interests are requested to combine their comments and 
present them through a single representative. The allocation of time 
may be adjusted to accommodate the level of expressed interest. DVIC 
will notify each presenter by mail or telephone of their assigned 
presentation time. Persons who do not file an advance request for a 
presentation, but desire to make an oral statement, may announce it 
at the time of the comment period. These persons will be allocated 
time as it permits.
    For Further Information Contact: Anyone requiring information 
regarding the ACCV should contact Michelle Herzog, DVIC, HSB, HRSA, 
Room 11C-26, 5600 Fishers Lane, Rockville, MD 20857; telephone (301) 
443-6593 or e-mail: mherzog@hrsa.gov.

    Dated: January 26, 2009.
Alexandra Huttinger,
Director, Division of Policy Review and Coordination.
[FR Doc. E9-2462 Filed 2-4-09; 8:45 am]
BILLING CODE 4165-15-P